SCHEMBL6902906

SCHEMBL6902906

CCOC(=O)Cn1nc(Oc2ccc(C(F)(F)F)cc2)cc1-c1cccc(C2(NC(=O)OC(C)(C)C)COC2)c1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPM2 O94759 1/20 0.37
FAAH O00519 1/20 0.35
PDE2A O00408 2/20 0.34
GRIN1 Q05586 2/20 0.34
GRIN2B Q13224 2/20 0.34
THRB P10828 1/20 0.33
BRAF P15056 3/20 0.33
SCN9A Q15858 2/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
XPO1 O14980 1/20 0.33
PIK3CD O00329 1/20 0.32
RAF1 P04049 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14717866 0.91 PDE2A (0.39) PDE2AGRIN1GRIN2BBRAFSCN9A
SCHEMBL14727913 0.88 TRPM2 (0.37) TRPM2FAAHPDE2AGRIN1GRIN2B
SCHEMBL6902871 0.84 SCN9A (0.37) GRIN1GRIN2BSCN9ASCN10APIK3CD
SCHEMBL1660744 0.79 PDE2A (0.38) PDE2AGRIN1GRIN2BBRAFSCN9A
SCHEMBL6903422 0.79 PDE2A (0.34) PDE2AGRIN1GRIN2BBRAFSCN9A
SCHEMBL6903551 0.77 PDE2A (0.36) PDE2ABRAFSCN9ASCN10APIK3CD
SCHEMBL1660015 0.76 PDE2A (0.36) PDE2ASCN9ASCN10APIK3CD
SCHEMBL14727841 0.76 SCN9A (0.37) SCN9A
SCHEMBL14719021 0.75 SCN9A (0.39) PDE2AGRIN1GRIN2BSCN9ASCN10A
SCHEMBL6903557 0.75 PDE2A (0.40) PDE2ATHRBBRAFSCN9ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
WO-2011046774-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS BACE1, BACE2, GSAP TRPM2 1744/4885FAAH 55/4885PDE2A 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.